应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
01801 信达生物
未开盘 11-09 16:08:05
86.450
+0.100
+0.12%
最高
88.900
最低
86.350
成交量
535.10万
今开
87.000
昨收
86.350
日振幅
2.95%
总市值
1,511亿
流通市值
1,511亿
总股本
17.48亿
成交额
4.67亿
换手率
0.31%
流通股本
17.48亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
【券商聚焦】中信建投评26 ESMO：中国创新药持续突破，竞争与差异化并存
金吾财讯 · 11-06
【券商聚焦】中信建投评26 ESMO：中国创新药持续突破，竞争与差异化并存
信达生物更新10月股份变动月报：已发行股份增至1,747,871,819股
公告速递 · 11-05
信达生物更新10月股份变动月报：已发行股份增至1,747,871,819股
港股异动 | 医药股继续走强 中生制药斩获70亿美元BD领涨 前三季BD出海接近去年全年
智通财经 · 11-05
港股异动 | 医药股继续走强 中生制药斩获70亿美元BD领涨 前三季BD出海接近去年全年
异动解读｜信达生物盘中上涨3.47%，券商看多叠加创新药板块走强
行情直击 · 11-05
异动解读｜信达生物盘中上涨3.47%，券商看多叠加创新药板块走强
【券商聚焦】招商证券维持信达生物（01801）强烈推荐评级 指产品收入创新高
金吾财讯 · 11-04
【券商聚焦】招商证券维持信达生物（01801）强烈推荐评级 指产品收入创新高
恒指午后走强涨超1%，创新药概念股强势拉升
老虎资讯综合 · 11-04
恒指午后走强涨超1%，创新药概念股强势拉升
异动解读｜信达生物盘中上涨3.09%，ESMO数据验证叠加国际化预期升温
行情直击 · 11-04
异动解读｜信达生物盘中上涨3.09%，ESMO数据验证叠加国际化预期升温
香港交易所：将于2027年1月18日推出12只新股票期货合约
智通财经 · 11-03
香港交易所：将于2027年1月18日推出12只新股票期货合约
港交所：明年1月18日推出12只新的股票期货合约，包含泡泡玛特、Minimax、智谱等标的
老虎资讯综合 · 11-03
港交所：明年1月18日推出12只新的股票期货合约，包含泡泡玛特、Minimax、智谱等标的
大行评级｜高盛：升信达生物目标价至122.28港元，评级“买入”
格隆汇 · 11-02
大行评级｜高盛：升信达生物目标价至122.28港元，评级“买入”
【券商聚焦】中信证券：国内医药板块业绩持续修复
金吾财讯 · 11-02
【券商聚焦】中信证券：国内医药板块业绩持续修复
港股概念追踪 | 2026年国产创新药海外BD交易额有望突破1500亿美元 海外商业化进入密集兑现阶段(附概念股)
智通财经 · 10-30
港股概念追踪 | 2026年国产创新药海外BD交易额有望突破1500亿美元 海外商业化进入密集兑现阶段(附概念股)
“基金买手”三季度重仓路径曝光，哪些主动权益基金被大幅增持？
澎湃新闻 · 10-29
“基金买手”三季度重仓路径曝光，哪些主动权益基金被大幅增持？
信达生物：2026年第三季度产品收入超47亿元 同比增长超40%
格隆汇 · 10-29
信达生物：2026年第三季度产品收入超47亿元 同比增长超40%
信达生物(01801)第三季度产品收入超过47亿元 同比增长超过40%
智通财经 · 10-29
信达生物(01801)第三季度产品收入超过47亿元 同比增长超过40%
信达生物制药（01801.HK）公布2026年三季度产品收入逾47亿元 同比增逾40%
公告速递 · 10-29
信达生物制药（01801.HK）公布2026年三季度产品收入逾47亿元 同比增逾40%
里昂：中国医疗健康板块近期回调属买入机会 海外及内地趋势改善
智通财经 · 10-28
里昂：中国医疗健康板块近期回调属买入机会 海外及内地趋势改善
异动解读｜信达生物盘中下跌3.02%，创新药板块整体走弱
行情直击 · 10-27
异动解读｜信达生物盘中下跌3.02%，创新药板块整体走弱
港股创新药概念股早盘走高！丽珠医药飙逾10%领涨，多家中国药企亮相ESMO年会，核心临床数据有望成股价催化剂
老虎资讯综合 · 10-26
港股创新药概念股早盘走高！丽珠医药飙逾10%领涨，多家中国药企亮相ESMO年会，核心临床数据有望成股价催化剂
亮相2026年欧洲肿瘤内科学会年会 信达生物发布坦康阿妥塔单抗胃癌Ⅲ期临床研究数据
证券日报 · 10-23
亮相2026年欧洲肿瘤内科学会年会 信达生物发布坦康阿妥塔单抗胃癌Ⅲ期临床研究数据
加载更多
公司概况
公司名称：
信达生物
所属市场：
SEHK
上市日期：
--
主营业务：
信达生物制药是一家主要从事研发、生产及销售治疗肿瘤、心血管及代谢（CVM）、自身免疫及眼科等重大疾病创新药物的投资控股公司。药物形式包括单克隆抗体、多特异性抗体、免疫细胞因子、抗体偶联药物（ADC）、细胞治疗及小分子药物等。该公司的主要产品包括达伯舒（信迪利单抗注射液）、达攸同（贝伐珠单抗注射液）、苏立信（阿达木单抗注射液）、达伯华（利妥昔单抗注射液）、达伯坦（佩米替尼片）等。该公司主要在中国国内和海外市场开展业务。
发行价格：
--
{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":86.45,"timestamp":1794211685005,"preClose":86.35,"halted":0,"volume":5350992,"delay":0,"changeRate":0.001158077591198709,"floatShares":1748000000,"shares":1748000000,"eps":0.469999,"marketStatus":"未开盘","change":0.1,"latestTime":"11-09 16:08:05","open":87,"high":88.9,"low":86.35,"amount":467395828,"amplitude":0.029531,"askPrice":86.45,"askSize":5000,"bidPrice":86.4,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":0.803379,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794274200000},"marketStatusCode":0,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":86.35,"openAndCloseTimeList":[[1794187800000,1794196800000],[1794200400000,1794211200000]],"volumeRatio":0.4198947579442066,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.5661,"impliedVolPercentile":0.8537},"requestUrl":"/m/hq/s/01801","defaultTab":"news","newsList":[{"id":"2681884019","title":"【券商聚焦】中信建投评26 ESMO：中国创新药持续突破，竞争与差异化并存","url":"https://stock-news.laohu8.com/highlight/detail?id=2681884019","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681884019?lang=zh_cn&edition=full","pubTime":"2026-11-06 08:57","pubTimestamp":1793926628,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年欧洲内科肿瘤学会（European Society for Medical Oncology，ESMO）中，中国创新药在多瘤种领域全面发力，众多项目从早期探索迈入III期临床或BLA/NDA阶段。国内药企已在IO双抗及多抗、ADC、小分子靶向等赛道形成多线并进格局，III期阳性终点多点开花，持续产出具备国际竞争力的临床数据，标志着中国创新药研发不断从跟随创新迈向源头创新与全球引领的新阶段，行业发展逻辑从“fast-follow”迈入“first-in-class”与“best-in-class”并行的阶段。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995351","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","LU0320764243.SGD","LU0315179316.USD","LU0128522744.USD","09995","LU1251922891.USD","601066","BK1574","KURE","LU1152091754.HKD","LU1188198961.HKD","LU0823426308.USD","LU1242518857.USD","LU2097828474.EUR","LU2097828714.EUR","LU0708995153.HKD","LU0455707207.USD","01177","LU2488822045.USD","LU1813983027.USD","LU1152091168.USD","LU0634319403.HKD","LU1960683339.HKD","09688","LU0039217434.USD","LU0516422952.EUR","BK1515","LU1226287529.USD","BK1583","LU0348766576.USD","LU0456827905.SGD","KCE","06160","LU0594300179.USD","02616","LU0417516571.SGD","LU0348783233.USD","LU0540923850.HKD","LU1807302812.USD","BK1191","02269","01801","LU1242518931.SGD","LU2242644610.SGD","06185","01093","IE00BPRC5H50.USD","01877","02142","LU0228659784.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146319508","title":"信达生物更新10月股份变动月报：已发行股份增至1,747,871,819股","url":"https://stock-news.laohu8.com/highlight/detail?id=1146319508","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146319508?lang=zh_cn&edition=full","pubTime":"2026-11-05 21:30","pubTimestamp":1793885447,"startTime":"0","endTime":"0","summary":"信达生物制药于2026年11月5日发布2026年10月股份变动月报。报告显示，截至10月31日，公司法定股本总额维持在5,000,000,000股，面值每股USD 0.00001，合计USD 50,000，未发生变动。报告期内，信达生物制药已发行股份由上月底的1,746,918,350股增至本月底的1,747,871,819股，增幅953,469股；无库存股发行或变动。公司于期间因期权行使共获资金约HKD 35,169,260.49。截至10月末，公司确认已满足适用的公众持股量要求，并在报告中声明所有股份发行均遵守香港联交所《上市规则》及相关法律规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681015969","title":"港股异动 | 医药股继续走强 中生制药斩获70亿美元BD领涨 前三季BD出海接近去年全年","url":"https://stock-news.laohu8.com/highlight/detail?id=2681015969","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681015969?lang=zh_cn&edition=full","pubTime":"2026-11-05 10:47","pubTimestamp":1793846861,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，医药股今早继续走高，创新药、CRO概念领衔。中国生物制药11月4日盘后公告，与跨国药企勃林格殷格翰就下一代肿瘤疗法达成重磅对外授权，覆盖6个创新药临床前项目。公司可获3.58亿美元首付款，潜在总额最高达70亿美元，刷新公司BD交易金额纪录。东方证券指出，从医药整体来看，2026年前三季度营收同比增长1.4%，归母净利润同比增长11.6%，扣非归母净利润同比增长18.3%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518838.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828631.EUR","BK1574","LU0607220059.USD","LU1969619763.USD","LU0244354667.USD","BK1583","IE00BZ08YT58.USD","LU1251922891.USD","LU2097828557.USD","LU2097828714.EUR","BK1589","LU1188198961.HKD","HK0000165453.HKD","BK4585","BK4588","LU2488822045.USD","06160","LU0149534421.HKD","BK1521","159938","KURE","LU0196878994.USD","BK1500","LU0588546209.SGD","01177","LU1719994722.HKD","BK1515","LU0228659784.USD","01477","LU0463099449.HKD","06990","LU2097828805.USD","KCAI","BK1191","LU1831875114.USD","VXUS","LU0650527681.SGD","BK1161","BK1588","IE00BZ08YR35.GBP","01801","LU0828237510.HKD","LU1770034418.SGD","LU2097828474.EUR","LU2242644610.SGD","LU1303224171.USD","LU2328871848.SGD","LU0594300179.USD","09939","LU0326950275.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156752954","title":"异动解读｜信达生物盘中上涨3.47%，券商看多叠加创新药板块走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1156752954","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156752954?lang=zh_cn&edition=full","pubTime":"2026-11-05 09:51","pubTimestamp":1793843514,"startTime":"0","endTime":"0","summary":"11月5日，信达生物盘中上涨3.47%，报88.45港元，成交额2.65亿港元。消息面上，市场继续消化券商看多观点及公司产品收入高增长。最新研报维持其强烈推荐评级，指出第三季度产品收入超47亿元，同比增长超40%，前三季度累计产品收入已超上年全年，商业化规模效应逐步体现；同时ESMO披露的核心管线数据积极，带动资金继续关注创新药主线。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"信达生物盘中上涨，创新药主线获资金关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680089564","title":"【券商聚焦】招商证券维持信达生物（01801）强烈推荐评级 指产品收入创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2680089564","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680089564?lang=zh_cn&edition=full","pubTime":"2026-11-04 13:45","pubTimestamp":1793771117,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招商证券发布研报指，信达生物 2026Q3产品收入再创新高，综合产品线持续放量，商业化规模效应逐步体现；ESMO数据显示核心管线关键数据积极。报告目标估值为NA，维持“强烈推荐”评级。截至2026H1已有20款商业化产品，13款纳入国家医保目录。2026H1IFRS净利润12.53亿元，同比增长50.2%，销售及市场推广费用占产品收入比例由45.4%降至39.5%。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995206","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","01801","06099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118961689","title":"恒指午后走强涨超1%，创新药概念股强势拉升","url":"https://stock-news.laohu8.com/highlight/detail?id=1118961689","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118961689?lang=zh_cn&edition=full","pubTime":"2026-11-04 13:39","pubTimestamp":1793770784,"startTime":"0","endTime":"0","summary":"11月4日，恒指午后走强涨超1%，创新药概念股强势拉升，$药明生物(02269)$、$药明康德(02359)$涨超9%，$荣昌生物(09995)$、$百济神州(ONC)$涨超8%，$药明合联(02268)$涨超7%，$信达生物(01801)$、$康方生物(09926)$涨超5%。","market":"hk","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1242518857.USD","LU1188198961.HKD","02800","LU2399975544.HKD","LU1328277881.USD","03037","LU1242518931.SGD","LU0708995583.HKD","BK1576","LU2328871848.SGD","LU0516423091.SGD","LU0348783233.USD","BK1588","LU3063872942.SGD","IE00BFMHRM44.USD","KURE","LU1813983027.USD","LU0043850808.USD","LU0326950275.SGD","LU1251922891.USD","MCHmain","LU0244354667.USD","LU0149721374.USD","BK1610","LU0594300179.USD","LU1303224171.USD","07300","BK4139","LNGR","LU0561508036.HKD","LU0417516571.SGD","LU1720050803.USD","IE00BPRC5H50.USD","LU0516422952.EUR","LU0140636845.USD","LU0543330566.HKD","LU0634319403.HKD","LU0417516902.SGD","LU0348735423.USD","LU0039217434.USD","LU0819121731.USD","02359","IE00B5MMRT66.SGD","LU0181495838.USD","02269","LU2125910500.SGD","LU0348784397.USD","06978","06160","LU2778985437.USD","HHImain","BK4526","159992","HSImain","09115","IE00B543WZ88.USD","LU0572944931.SGD","LU0708995153.HKD","BK1583","LU1831875114.USD","LU0456827905.SGD","LU1770034418.SGD","BK4588","LU0229945570.USD","LU0502904849.HKD","LU0516422440.USD","03115","LU2476274308.USD","LU0307460666.USD","LU0828237510.HKD","LU0359202008.SGD","LU2039709279.SGD","83115","SG9999011746.SGD","LU1481107354.HKD","LU0072913022.USD","LU0348827113.USD","82800","LU0052750758.USD","MHImain","LU1794554557.SGD","ONC","LU1961090484.USD","SG9999002463.SGD","LU0320764243.SGD","LU1688375341.USD","513600","LU0469268626.HKD","BK4585","LU1719994722.HKD","LU0588546209.SGD","LU0607220059.USD","SG9999002562.SGD","LU0516423174.USD","LU2242644610.SGD","LU1969619763.USD","LU0650527681.SGD","02833","BK1141","LU0128522744.USD","LU0463099449.HKD","LU0516422366.SGD","LU0314109678.HKD","LU0128526141.USD","LU0501845795.SGD","LU2045819591.USD","LU2097828805.USD","LU0540923850.HKD","HSI","03419","LU0149534421.HKD","LU2476274720.SGD","LU0455707207.USD","LU0856984785.SGD","LU0164880469.USD","LU2097828474.EUR","IBBQ","LU0320764599.SGD","LU2097828631.EUR","SG9999014674.SGD","LU0348767384.USD","BK1521","HK0000165453.HKD","LU1880383366.USD","LU0348766576.USD","LU0348825331.USD","LU2097828557.USD","09926","07200","LU0029874905.USD","LU0211977185.USD","LU0605514214.HKD","02268","LU0228659784.USD","LU0327786744.USD","LU0823426308.USD","LU1046422090.SGD","LU0456846285.SGD","07500","LU0594300419.USD","09995","IE00B0JY6N72.USD","LU2097828714.EUR","LU0979878070.USD","MEDX","01801","BK1589","LU0823426480.USD","LU2488822045.USD","BK1574","LU0029874061.USD","LU0051755006.USD","BK1161","LU0359201612.USD","BK1500","LU0417516738.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162692595","title":"异动解读｜信达生物盘中上涨3.09%，ESMO数据验证叠加国际化预期升温","url":"https://stock-news.laohu8.com/highlight/detail?id=1162692595","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162692595?lang=zh_cn&edition=full","pubTime":"2026-11-04 13:07","pubTimestamp":1793768827,"startTime":"0","endTime":"0","summary":"11月4日，信达生物盘中上涨3.09%，报81.8港元，成交额3.57亿港元。消息面上，市场继续消化公司近期在ESMO披露的临床进展及机构看多观点，带动生物科技板块走强。公司此前公布，坦康阿妥塔单抗治疗晚期胃癌的国际多中心Ⅲ期研究达到双重主要终点；第三季度产品收入超过47亿元，同比增长超过40%。同时，多家机构近期表示中国创新药ESMO数据再获验证，并看好其海外商业化与估值重估空间。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"信达生物上涨，ESMO数据验证叠加国际化预期升温","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680174581","title":"香港交易所：将于2027年1月18日推出12只新股票期货合约","url":"https://stock-news.laohu8.com/highlight/detail?id=2680174581","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680174581?lang=zh_cn&edition=full","pubTime":"2026-11-03 16:29","pubTimestamp":1793694566,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，11月3日，香港交易及结算所有限公司宣布，将于2027年1月18日(星期一)推出12只新的股票期货合约。香港交易所持续扩展衍生产品系列，增加投资者的选择，让市场参与者更灵活地满足交易及风险管理需要。新股票期货合约将与香港交易所部分交投最活跃的个股期权相辅相成，进一步丰富以这些股票为相关资产的衍生产品种类。新股票期货合约首六个月的香港证监会征费将可获得豁免。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517715.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0762542818.HKD","LU0862451837.USD","SG9999001143.SGD","LU1130305938.SGD","LU0880133367.SGD","LU0169518387.USD","LU0918141887.USD","LU0197773673.USD","LU0455707207.USD","LU0516423174.USD","LU1282649141.HKD","LU0630378692.HKD","LU0348827113.USD","LU0469268626.HKD","LU0251144936.SGD","LU0348767384.USD","HK0000107257.USD","HK0000320223.HKD","LU0039217434.USD","LU0345780950.USD","LU0650527681.SGD","LU0211977185.USD","LU0359201885.HKD","BK1249","LU1366334578.USD","SG9999006597.SGD","LU0784639295.USD","BK1576","LU0630314457.HKD","LU1044876610.USD","LU0140636845.USD","LU0348816934.USD","LU1808992512.USD","LU0345776255.USD","LU2097828714.EUR","SG9999002463.SGD","LU1224709979.USD","LU0594300419.USD","LU1152091754.HKD","IE00BZ08YT58.USD","BK1116","LU1267930227.SGD","LU1023057109.AUD","LU0029875118.USD","LU0577902611.USD","LU0049112450.USD","IE00B3T34201.USD","LU0197773160.USD","LU1171460220.USD","LU2257852520.SGD","LU0593848301.USD","06869","LU1044874839.SGD","LU0048580855.USD","LU0831103253.SGD","LU1303224171.USD","09992","LU0196878994.USD","LU0821914370.USD","SG9999001093.SGD","01378","LU0762540952.USD","LU0797268264.HKD","SGXZ90724238.SGD","LU1235295612.USD","LU2213484517.USD","LU0052756011.USD","LU0890818403.SGD","LU0577902298.EUR","LU1831875114.USD","00388","LU0516423091.SGD","LU1515016050.SGD","LU2097828631.EUR","LU0516422440.USD","LU0117844026.USD","LU0873338254.USD","LU1960683339.HKD","01801","BK1163","LU1048588211.SGD","LU0572940350.SGD","LU1251922891.USD","LU0106959298.USD","LU0348825331.USD","LU0531971595.HKD","LU1166156734.SGD","HK0000306685.HKD","LU1048596156.SGD","LU1993786604.SGD","LU0117841782.USD","LU0307460666.USD","SG9999002562.SGD","BK1523","LU2279858448.HKD","HK0001040143.USD","LU0955669360.SGD","LU1188198961.HKD","LU0048597586.USD","LU0819121731.USD","SG9999001069.SGD","BK1224","LU0210527791.USD","LU0488056044.USD","LU0898667661.SGD","HK0000306701.USD","BK1614","BK1506","BK1610","LU1008478684.HKD","LU1785774172.SGD","LU0979878070.USD","LU0577902454.USD","LU0164865239.USD","LU0164880469.USD","LU0345775950.USD","LU0918141705.HKD","LU0516422952.EUR","BK1589","IE00BKZH1Z71.USD","LU0702159699.USD","LU0823426308.USD","LU0871576103.HKD","LU2242644610.SGD","LU0516422366.SGD","LU0823426480.USD","LU1051768304.USD","LU0084288322.USD","LU0499858438.USD","BK1592","LU0856984785.SGD","LU0588546209.SGD","BK1175","LU0708995583.HKD","LU0011963245.USD","LU0605514214.HKD","LU0417516902.SGD","LU0683595622.HKD","IE0034224299.USD","LU1642822792.SGD","HKXCY","LU0501845795.SGD","LU1734074674.USD","LU2328871848.SGD","LU0651946864.USD","LU0348814723.USD","LU0791591158.USD","BK1526","BK1607","KURE","LU1206782309.USD","LU0128522157.USD","LU1105468828.SGD","LU2039709279.SGD","LU0314109678.HKD","LU1226287529.USD","601869","LU0648948544.HKD","300750","LU1046422090.SGD","LU1328277881.USD","LU1282649067.USD","00100","LU1242518857.USD","80992","LU0577902538.SGD","02513","BK1594","LU0327786744.USD","LU0345780521.USD","LU0345780281.USD","LU0463099449.HKD","LU0633140727.USD","LU0762541174.USD","LU0955623706.USD","LU0540923850.HKD","LU1051769294.HKD","LU2125910500.SGD","LU0831093199.SGD","80388","BK1122","LU0096374516.USD","LU0149721374.USD","LU0261947096.USD","LU1719994722.HKD","LU0149534421.HKD","IE00BZ08YS42.EUR","LU0543330483.HKD","LU1481107354.HKD","LU0264606111.USD","PMRTY","02259","BK1583","LU0417516738.SGD","LU2543165471.USD","LU1655091616.SGD","BK1521","IE00B0JY6N72.USD","01347","LU0611395673.USD","LNVGY","HK0000500386.USD","LU0310800965.SGD","LU1282648689.USD","LU1880383366.USD","LU2097828805.USD","688347","LU0791590937.USD","LU1152091168.USD","SGXZ62798434.SGD","BK1149","SGXZ86797644.SGD","LU0165289439.USD","BK1198","LU0052750758.USD","LU0607220059.USD","LU0634319403.HKD","LU0326950275.SGD","LU0244354667.USD","LU0672654166.SGD","BK1193","LU1655091459.SGD","IE0003851619.USD","LU1770036033.HKD","LU0633140560.USD","LU0370786039.SGD","LU0819123356.HKD","LU1880383440.USD","LU1969619763.USD","LU2488822045.USD","LU1282649810.SGD","SG9999001051.SGD","LU1981816686.USD","LU0320764599.SGD","BK1141","LU0561508036.HKD","LU0043850808.USD","LU0651947912.USD","LU2226246903.HKD","HK0000252160.HKD","LU3227948356.SGD","LU0231483743.USD","BK1131","LU0862451753.SGD","603259","LU0173614495.USD","LU0348766576.USD","LU0737861699.HKD","SG9999002950.SGD","LU0345781412.USD","LU0072462343.USD","300308","LU0348735423.USD","IE0003795394.USD","LU1211504680.USD","LU1044875133.USD","SG9999004220.SGD","00992","LU0594300179.USD","LU0359202008.SGD","LU1807302812.USD","LU0067412154.USD","HK0001040168.HKD","LU0499858602.USD","LU1242518931.SGD","BK1161","LU0287142896.SGD","03750","LU2449936058.SGD","BK1117","HK0000151867.HKD","LU0456846285.SGD","LU0572939691.SGD","IE0003895053.USD","03308","HK0000320264.USD","IE00BZ08YR35.GBP","HK0000252152.HKD","LU0502904849.HKD","LU0630378429.USD","LU0886674414.USD","LU1255011170.USD","LU1366334651.USD","LU0072913022.USD","HK0000165453.HKD","02359","BK1500","LU0972618739.USD","LU0128525689.USD","LU0955648018.USD","BK1533","SG9999001846.SGD","TCHI","LU0061477393.USD","LU0577902371.SGD","LU1813983027.USD","LU2045819591.USD","LU2097828557.USD","LU0572944931.SGD","LU0359201612.USD","LU1504937902.USD","LU1770034418.SGD","LU2097828474.EUR","IE0032431581.USD","LU0320764755.SGD","LU0384037296.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147122839","title":"港交所：明年1月18日推出12只新的股票期货合约，包含泡泡玛特、Minimax、智谱等标的","url":"https://stock-news.laohu8.com/highlight/detail?id=1147122839","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147122839?lang=zh_cn&edition=full","pubTime":"2026-11-03 16:19","pubTimestamp":1793693981,"startTime":"0","endTime":"0","summary":"香港交易所今天（星期二）宣布，将于2027年1月18日（星期一）推出12只新的股票期货合约。香港交易所持续扩展衍生产品系列，增加投资者的选择，让市场参与者更灵活地满足交易及风险管理需要。新股票期货合约将与香港交易所部分交投最活跃的个股期权相辅相成，进一步丰富以这些股票为相关资产的衍生产品种类。新股票期货合约首六个月的证监会征费将可获得豁免。将推出的新股票期货合约包括：","market":"us","thumbnail":"https://static.tigerbbs.com/f29dcd24b023d4290cb189dcda6d718e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f29dcd24b023d4290cb189dcda6d718e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"港交所：明年1月18日推出12只新的股票期货合约，包含泡泡玛特、Minimax、智谱等标的","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06869","01801","02513","03308","00992","03750","00100","02259","01347","02359","09992","01378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680784164","title":"大行评级｜高盛：升信达生物目标价至122.28港元，评级“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2680784164","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680784164?lang=zh_cn&edition=full","pubTime":"2026-11-02 11:01","pubTimestamp":1793588498,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0607220059.USD","LU2097828557.USD","01801","LU2097828714.EUR","LU0463099449.HKD","LU0605514214.HKD","LU1969619763.USD","LU2097828805.USD","LU0244354667.USD","LU1188198961.HKD","LU0502904849.HKD","BK1583","BK1589","HK0000165453.HKD","LU2097828631.EUR","LU0594300179.USD","LU2488822045.USD","LU2242644610.SGD","LU0149534421.HKD","LU0326950275.SGD","BK1161","LU2097828474.EUR","LU0650527681.SGD","LU2328871848.SGD","KURE","LU0455707207.USD","LU0594300419.USD","LU1831875114.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680717785","title":"【券商聚焦】中信证券：国内医药板块业绩持续修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2680717785","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680717785?lang=zh_cn&edition=full","pubTime":"2026-11-02 08:40","pubTimestamp":1793580014,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券发布2027年医疗健康行业投资策略，“十五五”开局之年，医药行业首次列为国家新兴支柱产业，紧随其后的价格机制优化改革 、支持创新药械高定价、以及推动商业医疗保险发展等行业增量改革政策趋势，叠加国内医药行业在创新领域集中兑现等产业内外催化因素驱动下，该机构看到2026H1国内医药板块业绩持续修复，尤其是创新药、创新器械等新兴产业板块。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994936","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530","00013","LU2488822045.USD","LU1226287529.USD","06821","LU0348766576.USD","06078","159938","06160","IE00B031HY20.USD","KURE","LU0607220059.USD","02268","02596","LU0708995153.HKD","HK0000320264.USD","LU0039217434.USD","LU1794554557.SGD","01276","LU0979878070.USD","01548","09939","LU0348825331.USD","01093","02162","01951","02269","LU0588546209.SGD","02096","01177","LU1969619763.USD","09966","06996","LU0455707207.USD","03692","LU0823426480.USD","06990","06030","LU1064131003.USD","LU0708995583.HKD","03759","LU0828237510.HKD","BK0028","02273","01801","09996","09926","KCE","01952","600030"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679258473","title":"港股概念追踪 | 2026年国产创新药海外BD交易额有望突破1500亿美元 海外商业化进入密集兑现阶段(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2679258473","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679258473?lang=zh_cn&edition=full","pubTime":"2026-10-30 07:17","pubTimestamp":1793315846,"startTime":"0","endTime":"0","summary":"全年潜在交易总额存在突破1500亿美元的可能，但最终规模仍取决于后续交易落地情况。2026年，全球主流药企的核心产品专利集中到期。2026年上半年，信达生物实现营业收入86.18亿元，同比增长44.76%；归母净利润12.53亿元，同比增长50.20%。此外，中国创新药在海外的临床开发取得进展，即将进入全球商业化阶段。2026年前三季度，公司新签订单同比增长超过30%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1515760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","IBBQ","LU0348767384.USD","LU1023057109.AUD","LU0149534421.HKD","BK1576","LU0320764599.SGD","LU0348766576.USD","BK1574","LU2543165471.USD","LU0572944931.SGD","MEDX","LU0502904849.HKD","LU0326950275.SGD","03759","LU0455707207.USD","BK1161","LU2045819591.USD","VXUS","KURE","02359","HK0000165453.HKD","LU0327786744.USD","LU1046422090.SGD","LU2328871848.SGD","BK1583","01801","06978","BK1141","LU2097828714.EUR","LU2097828805.USD","BK4588","LU0469268626.HKD","LU0072913022.USD","LU0359202008.SGD","LU0501845795.SGD","LU0052750758.USD","LU2125910500.SGD","LNGR","LU1188198961.HKD","LU0359201612.USD","LU0359201885.HKD","LU2488822045.USD","KCAI","BK1191","LU0244354667.USD","LU2242644610.SGD","01276","LU2097828631.EUR","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679285027","title":"“基金买手”三季度重仓路径曝光，哪些主动权益基金被大幅增持？","url":"https://stock-news.laohu8.com/highlight/detail?id=2679285027","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679285027?lang=zh_cn&edition=full","pubTime":"2026-10-29 22:00","pubTimestamp":1793282441,"startTime":"0","endTime":"0","summary":"“基金买手”三季度重仓路径曝光，哪些主动权益基金被大幅增持？","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610293914932760.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610293914932760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","LU1997245177.USD","LU0455707207.USD","LU2495084118.USD","SG9999002463.SGD","LU0149534421.HKD","LU2242644610.SGD","LU0039217434.USD","BK0239","LU1188198961.HKD","LU2097828631.EUR","LU2097828714.EUR","BK0070","LU0463099449.HKD","LU1720050803.USD","BK1589","LU0051755006.USD","LU0607220059.USD","601318","LU2399975544.HKD","LU1580142542.USD","LU1934453819.USD","LU2148510915.USD","LU2213484517.USD","LU0405327494.USD","BK0012","BK0196","BK0187","688266","LU0456827905.SGD","LU0502904849.HKD","HK0000181138.USD","LU0244354667.USD","LU2097828474.EUR","LU1655091616.SGD","IE0005HP3H50.USD","BK0183","LU1831875114.USD","LU0326950275.SGD","LU2097828805.USD","LU1064130708.USD","BK1161","01801","LU0456846285.SGD","LU1794554557.SGD","LU1064131003.USD","LU1781817850.SGD","KURE","LU1997244956.HKD","HK0000181112.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679443012","title":"信达生物：2026年第三季度产品收入超47亿元 同比增长超40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679443012","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679443012?lang=zh_cn&edition=full","pubTime":"2026-10-29 07:47","pubTimestamp":1793231221,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["KURE","LU2097828474.EUR","BK1583","LU0326950275.SGD","BK1161","LU2328871848.SGD","LU1969619763.USD","LU0244354667.USD","01801","LU2242644610.SGD","LU2097828557.USD","LU1831875114.USD","HK0000165453.HKD","LU0607220059.USD","LU0455707207.USD","LU0149534421.HKD","LU0463099449.HKD","BK1589","LU2097828805.USD","LU1188198961.HKD","LU2097828714.EUR","LU0502904849.HKD","LU2488822045.USD","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679267443","title":"信达生物(01801)第三季度产品收入超过47亿元 同比增长超过40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679267443","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679267443?lang=zh_cn&edition=full","pubTime":"2026-10-29 07:38","pubTimestamp":1793230692,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物 发布公告，于2026年第三季度，本公司业务延续强劲增长势头，产品收入超过人民币47亿元，同比增长超过40%，充分印证双轮驱动战略的强劲动能与持续兑现。面向2030年，本公司锚定核心战略目标：致力于实现总收入人民币350亿至400亿元、跻身一流药企利润率水平、推动至少五个候选分子进入全球多中心III期开发，并实现产品在主要欧美市场上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1514777.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828557.USD","LU2097828805.USD","LU2488822045.USD","LU0326950275.SGD","BK1583","LU0455707207.USD","LU2242644610.SGD","LU1188198961.HKD","01801","LU1831875114.USD","LU0149534421.HKD","LU0502904849.HKD","BK1589","LU0607220059.USD","HK0000165453.HKD","LU2097828714.EUR","BK1161","LU2097828474.EUR","LU2328871848.SGD","LU2097828631.EUR","KURE","LU0244354667.USD","LU1969619763.USD","LU0463099449.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117269603","title":"信达生物制药（01801.HK）公布2026年三季度产品收入逾47亿元 同比增逾40%","url":"https://stock-news.laohu8.com/highlight/detail?id=1117269603","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117269603?lang=zh_cn&edition=full","pubTime":"2026-10-29 07:35","pubTimestamp":1793230557,"startTime":"0","endTime":"0","summary":"2026年10月29日，信达生物制药发布内幕消息公告称，2026年第三季度公司实现产品收入超过人民币47亿元，同比增幅超过40%。实现总收入人民币350亿至400亿元；信达生物制药同时提示，本次披露的财务数据基于内部管理记录，未经外聘核数师审阅，仅供投资者参考。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678459668","title":"里昂：中国医疗健康板块近期回调属买入机会 海外及内地趋势改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2678459668","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678459668?lang=zh_cn&edition=full","pubTime":"2026-10-28 16:03","pubTimestamp":1793174593,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，里昂发布研报称，中国医疗健康板块近期回调主要受宏观忧虑推动，相关因素大致已反映于股价;海外进展及内地营运持续改善，宏观环境亦已企稳，该行视近期回调为买入机会。于ESMO 2026，中国资产占96项LBA中的29项，以及12场Presidential Symposium中的5场。该行维持中国医疗健康股票篮子不变，指医疗健康占基金总持仓不足2%，估值折让提供更具吸引力的长线买入机会;进一步海外临床进展及新的III期资产BD交易亦应为板块提供支持。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1514114.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828805.USD","BK4550","BK4588","LU0417516902.SGD","IE00B031HY20.USD","LABU","LU1226288170.HKD","BK1574","IE00B5MMRT66.SGD","LU0607220059.USD","LU2328871848.SGD","IE0008369823.USD","LU0417516571.SGD","LU1226288253.USD","LU2399975544.HKD","LU0326950275.SGD","LU1008478684.HKD","LU2488822045.USD","LU0348783233.USD","LU1226287875.USD","XLV","09887","BK1191","159760","LU2097828631.EUR","IE00BPRC5H50.USD","06990","BK4581","BK1589","01801","KURE","BK1583","XBI","VHT","IXJ","LU0561508036.HKD","LU0417516738.SGD","LU1969619763.USD","LU0196878994.USD","LU2476274720.SGD","LU1328277881.USD","01093","BK1521","LU1813983027.USD","LU0348766576.USD","LU0501845795.SGD","02595","IE00BZ08YS42.EUR","09926","LU1993786604.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152185603","title":"异动解读｜信达生物盘中下跌3.02%，创新药板块整体走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1152185603","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152185603?lang=zh_cn&edition=full","pubTime":"2026-10-27 14:11","pubTimestamp":1793081489,"startTime":"0","endTime":"0","summary":"10月27日，信达生物盘中下跌3.02%，报80.2港元，成交额4.84亿港元。当日生物科技板块多股走弱，康方生物跌3.86%，映恩生物-B跌31.19%，康诺亚-B跌13.83%，科伦博泰生物跌6.04%，百济神州跌3.03%，信达生物股价同步承压。公司近期虽在ESMO公布胃癌Ⅲ期及ADC等临床进展，但当下更直接反映的是板块回调带来的压力。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"信达生物盘中下跌，创新药板块承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154287539","title":"港股创新药概念股早盘走高！丽珠医药飙逾10%领涨，多家中国药企亮相ESMO年会，核心临床数据有望成股价催化剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1154287539","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154287539?lang=zh_cn&edition=full","pubTime":"2026-10-26 10:16","pubTimestamp":1792981015,"startTime":"0","endTime":"0","summary":"据国联民生证券研究显示，本届ESMO年会合计有96项最新突破成果摘要公布，其中31项为中国公司旗下药物相关研究。预计多项核心数据有望成为相关上市公司的近期股价催化剂。华泰证券发布研报表示，近日ADC赛道进展频现。ESMO年会上，多款ADC类药物展现良好疗效，继续验证其作为下一代肿瘤治疗基石药物的潜力。和ADC有关的授权交易持续落地，交易金额持续走高。","market":"hk","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","02162","02359","06990","09688","01548","01513","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677978128","title":"亮相2026年欧洲肿瘤内科学会年会 信达生物发布坦康阿妥塔单抗胃癌Ⅲ期临床研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2677978128","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677978128?lang=zh_cn&edition=full","pubTime":"2026-10-23 21:53","pubTimestamp":1792763580,"startTime":"0","endTime":"0","summary":"亮相2026年欧洲肿瘤内科学会年会 信达生物发布坦康阿妥塔单抗胃癌Ⅲ期临床研究数据","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610233906689776.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610233906689776.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2328871848.SGD","01801","BK1161","LU0607220059.USD","LU0455707207.USD","LU1831875114.USD","LU1969619763.USD","HK0000165453.HKD","LU2097828557.USD","LU1188198961.HKD","LU2097828474.EUR","BK1583","LU0502904849.HKD","LU2097828631.EUR","LU2097828714.EUR","BK1589","LU0326950275.SGD","LU0149534421.HKD","LU0244354667.USD","LU2097828805.USD","LU0463099449.HKD","LU2488822045.USD","KURE","LU2242644610.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":0.0719},{"period":"1month","weight":-0.0669},{"period":"3month","weight":-0.0952},{"period":"6month","weight":-0.0069},{"period":"1year","weight":0.0147},{"period":"ytd","weight":0.1338}],"compareEarnings":[{"period":"1week","weight":0.0451},{"period":"1month","weight":0.0098},{"period":"3month","weight":-0.0469},{"period":"6month","weight":-0.0735},{"period":"1year","weight":-0.0683},{"period":"ytd","weight":-0.0461}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"信达生物制药是一家主要从事研发、生产及销售治疗肿瘤、心血管及代谢（CVM）、自身免疫及眼科等重大疾病创新药物的投资控股公司。药物形式包括单克隆抗体、多特异性抗体、免疫细胞因子、抗体偶联药物（ADC）、细胞治疗及小分子药物等。该公司的主要产品包括达伯舒（信迪利单抗注射液）、达攸同（贝伐珠单抗注射液）、苏立信（阿达木单抗注射液）、达伯华（利妥昔单抗注射液）、达伯坦（佩米替尼片）等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.041076},{"month":2,"riseRate":0.75,"avgChangeRate":0.110526},{"month":3,"riseRate":0.25,"avgChangeRate":-0.01934},{"month":4,"riseRate":0.75,"avgChangeRate":0.043223},{"month":5,"riseRate":0.375,"avgChangeRate":0.014737},{"month":6,"riseRate":0.625,"avgChangeRate":0.116146},{"month":7,"riseRate":0.5,"avgChangeRate":0.019948},{"month":8,"riseRate":0.75,"avgChangeRate":0.024842},{"month":9,"riseRate":0.5,"avgChangeRate":0.021235},{"month":10,"riseRate":0.25,"avgChangeRate":-0.043332},{"month":11,"riseRate":0.666667,"avgChangeRate":0.07971},{"month":12,"riseRate":0.375,"avgChangeRate":0.024026}],"exchange":"SEHK","name":"信达生物","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}